Compare MSAI & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSAI | IMRN |
|---|---|---|
| Founded | 1995 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 9.6M |
| IPO Year | 2021 | 2016 |
| Metric | MSAI | IMRN |
|---|---|---|
| Price | $5.35 | $1.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $110.00 | N/A |
| AVG Volume (30 Days) | 15.9K | ★ 20.5K |
| Earning Date | 05-14-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,551,000.00 | N/A |
| Revenue This Year | $98.45 | N/A |
| Revenue Next Year | $38.89 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.15 | $0.68 |
| 52 Week High | $7.94 | $2.38 |
| Indicator | MSAI | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 56.30 | 47.77 |
| Support Level | $5.40 | $1.07 |
| Resistance Level | $5.79 | $1.24 |
| Average True Range (ATR) | 0.35 | 0.07 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 81.17 | 43.96 |
MultiSensor AI Holdings Inc builds and deploys integrated condition monitoring and early threat detection solutions through a unified edge-to-cloud software architecture, delivering AI-powered connected intelligence and analytics for asset reliability and performance. The Company's platform integrates multiple sensing modalities such as thermal, visual, and vibration to detect mechanical, electrical, and other modes of asset failure, enabling organizations operating high-throughput, automation-rich, and power-dense facilities to protect uptime, enhance safety, and extend the useful life of their critical assets.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.